Remove 2030 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmTech

Pharmaceutical companies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Challener News Article Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise. Siemens Finalizes $5.1B

Dosage 64
article thumbnail

ten23 health Joins Gerresheimer, SCHOTT, Stevanato Group in ‘Alliance for RTU’

PharmTech

The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceutical companies, contract manufacturers, and contract development and manufacturing organizations.

Dosage 45
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BioNTech pledges major UK investment

European Pharmaceutical Review

It is one of the biggest investments in UK history for a pharmaceutical company. The multi-year partnership with the UK government aims to provide up to 10,000 patients with investigational personalised cancer immunotherapies by 2030, according to the UK governments Department for Science, Innovation and Technology (DSIT).

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceutical companies make data public in real time. What are the associated challenges? Conclusion.

article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

article thumbnail

Could virtual reality become an essential tool for healthcare education?

pharmaphorum

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145